ArticleBrain & spine2025
Patient satisfaction and quality of life with hemifacial spasm treatments in Finland's largest hospital district.
Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemifacial spasm (HFS) treatments aim to remove involuntary facial twitching and improve the Quality of Life (QoL). No previous publications about overall patient treatment satisfaction or the impact of radiofrequency thermocoagulation (RFT) on patient satisfaction or QoL are available. Research question: This study describes patient satisfaction and QoL overall and in different treatment allocations. Material and methods: This cross-sectional questionnaire-based study was conducted in the Hospital District of Helsinki and Uusimaa (HUS). Consecutive HFS patients who had botulinum toxin (BTX), RFT, or microvascular decompression (MVD) between 2014 and 2019 were included. The participants answered HFS-7, 15D, and questions about treatment satisfaction and background. Results: 59.40 % (N = 139) of contacted HFS patients in HUS (population responsibility 1.6 million) participated (82 female, 57 male). 79.14 % of patients were satisfied or very satisfied with the overall treatment. Most often, patients were satisfied with BTX (76.81 %). 52.63 % were satisfied with RFT, and 24.00 % with MVD. The mean HFS-7 scores for overall treatment, BTX, MVD, and RFT were 1.10, 1.13, 0.40, and 0.79 (scale 0-4). The mean 15D scores for overall treatment, BTX, MVD, and RFT were 0.87, 0.78, 0.91, and 0.86 (scale 0-1).Having RFT correlated negatively to BTX treatment satisfaction (p < 0.001, effect size 0.449). Patients were more satisfied with RFT results if the duration of relief in facial twitching lasted longer (p0.034, effect size 0.580). Discussion and conclusion: Patients are satisfied with the overall treatment. Treatment satisfaction does not correlate with QoL. QoL after RFT seems comparable with other treatment allocations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.